The genetic characteristics of a tumor are becoming increasingly important in determining the treatment strategy for advanced prostate cancer. Modern oncology is gradually moving away from a one-size-fits-all approach toward personalized treatment based on the molecular features of each patient’s disease.
Updated recommendations from the American Urological Association (AUA) and the Society of Urologic Oncology (SUO), published in early October, emphasize the growing role of genetic testing. This includes both somatic testing, which identifies genetic alterations within tumor cells, and germline testing for inherited mutations.
Particular attention is being paid to genes involved in DNA damage repair, including BRCA1 and BRCA2. Mutations in these genes may directly influence treatment decisions and help identify patients who could benefit from specific targeted therapies.
TALAPRO-3: Risk of Progression Reduced by Approximately 52%
One of the most significant recent studies in this field is TALAPRO-3, with results published in 2026 in the New England Journal of Medicine.
The trial included 599 patients with metastatic hormone-sensitive prostate cancer and alterations in DNA repair genes.
Researchers evaluated the effectiveness of combining the PARP inhibitor talazoparib with enzalutamide. The results showed that adding talazoparib reduced the risk of disease progression or death by approximately 52% compared with the control group.
After three years, 77% of patients receiving the combination therapy remained free from disease progression, compared with 56% in the control group.
The benefit was particularly pronounced among patients with BRCA mutations.
AMPLITUDE Confirms the Importance of Tumor Genetics
Additional evidence comes from the AMPLITUDE trial, published in Nature Medicine.
The study included 696 patients with alterations in genes responsible for DNA repair. Researchers investigated the effectiveness of adding the PARP inhibitor niraparib to abiraterone and standard hormonal therapy.
The combination reduced the risk of radiographic disease progression or death by 37%.
Among patients with BRCA1 or BRCA2 mutations, the effect was even more substantial, with the risk reduced by 48%.
Taken together, the findings from these major clinical trials demonstrate that the genetic profile of a tumor can play an important role in selecting treatment for metastatic prostate cancer.
Why Genetic Testing Is Becoming an Important Part of Prostate Cancer Care
Modern cancer treatment is increasingly based not only on the location and stage of a tumor but also on its molecular and genetic characteristics.
Identifying specific mutations can help physicians determine which treatments are more likely to be effective for an individual patient. In addition, the discovery of inherited mutations such as BRCA1 or BRCA2 may have implications not only for the patient but also for close family members.
For patients with advanced prostate cancer, molecular and genetic testing is therefore becoming an increasingly important component of comprehensive diagnostics and treatment planning.
Sapir Medical helps international patients obtain consultations with leading Israeli oncologists and uro-oncologists, arrange advanced diagnostic testing, and receive a second medical opinion regarding the most appropriate treatment strategy for prostate cancer.
Genetic test results alone do not determine a treatment plan. Decisions regarding specific therapies must be made by a qualified physician based on the stage and characteristics of the disease, previous treatments, the patient’s overall health, and other relevant clinical factors.